A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC
The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without chemotherapy in the treatment of unresectable stage III non-small cell lung cancer
Non-Small-Cell Lung Cancer
DRUG: SHR-1701+Paclitaxel+carboplatin|DRUG: SHR-1701
ORR, Objective response rate, From the initiation of the first dose to 3 years|EFS, event free survival, From the initiation of the first dose to 3 years
OS, overall survival, From the initiation of the first dose to 3 years|EFS rate, event free survival rate, From the initiation of the first dose to 3 years|TDDM, time to death or distant metastasis, From the initiation of the first dose to 3 years|Adverse events(AEs), Incidence of treatment-related AEs, From the initiation of the first dose to 90 days after the last dose
The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without chemotherapy in the treatment of unresectable stage III non-small cell lung cancer